Pyxis Oncology

Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.

pharma lab worker ai

Analyst Color

Biotech

News

Health Care

Analyst Ratings

General

PYXS

Pyxis Oncology prioritizes PYX-201 with promising Phase 1 results in solid tumors, while deprioritizing PYX-106 due to resource allocation and challenges.

Pyxis Oncology&#39;s Deprioritizes Second Pipeline Asset, Analyst Applauds Move

Baidu Photo by testing on Shutterstock

Earnings

Equities

Eurozone

Commodities

Markets

Trading Ideas

BIDU

CLCO

KURA

QUBT

SNOW

Nasdaq Edges Higher; Baidu Shares Fall After Q3 Results

oil-prices-5079975

Intraday Update

Crude Oil Gains 1%; Deere Posts Better-Than-Expected Earnings

Pyxis Oncology Inc

Press Releases

Pyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024

Pyxis Oncology to Participate in Two Upcoming Investor Conferences

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Pyxis Oncology, Inc. (NASDAQ:PYXS)

Pyxis Oncology to Host In-Person (NYC) and Virtual Investor Event on Wednesday, November 20, 2024, to Present Preliminary Data from the Phase 1 Dose Escalation Trial of PYX-201

Pyxis Oncology Provides Corporate Update and Reports Financial Results for Third Quarter 2024

Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data

Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201

Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial

Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer

Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference

Acumen Pharmaceuticals, Inc. - Common Stock

Acumen Pharmaceuticals

Adicet Bio

Achilles Therapeutics plc - American Depositary Shares

Achilles Therapeutics

Applied Therapeutics, Inc. - Common Stock

Applied Therapeutics

Armata Pharmaceuticals, Inc. Common Stock

Armata Pharmaceuticals

Assembly Biosciences, Inc. - Common Stock

Assembly Biosciences

Aerovate Therapeutics, Inc. - Common Stock

Aerovate Therapeutics

BeyondSpring

Cibus

Citius Oncology

Cue Biopharma

Genenta Science S.p.A. - American Depositary Shares

Genenta Science

I-MAB

Inovio Pharmaceuticals, Inc. - Common Stock

Inovio Pharmaceuticals

Inozyme Pharma

IO Biotech

Mersana Therapeutics, Inc. - Common Stock

Mersana Therapeutics

Mural Oncology

OnKure Therapeutics, Inc. - Class A Common Stock

OnKure Therapeutics

PepGen

PMV Pharma

Quince Therapeutics

Tonix Pharmaceuticals Holding Corp. - Common Stock

Tonix Pharmaceuticals

Tenaya Therapeutics

X4 Pharmaceuticals

HC Wainwright & Co.

RBC Capital

Stephens & Co.

Stifel

Jefferies

Comments

Pyxis Oncology

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga